Tracheobronchopathy From Inhaled Corticosteroids

Inhaled corticosteroids (ICSs) have become the mainstay of asthma control. They are also recommended as an add-on therapy to long-acting beta agonists and anticholinergics in moderate to severe COPD with recurrent exacerbations. Ultimately this clinical practice has led to the widespread use of ICSs, which are supported by a more favorable side effect profile than that of systemic steroids. Inhaled corticosteroids (ICSs) have become the mainstay of asthma control. They are also recommended as an add-on therapy to long-acting beta agonists and anticholinergics in moderate to severe COPD with recurrent exacerbations. Ultimately this clinical practice has led to the widespread use of ICSs, which are supported by a more favorable side effect profile than that of systemic steroids. Errors in Table 1 in: Tracheobronchopathy From Inhaled CorticosteroidsCHESTVol. 155Issue 1PreviewThe authors have reported to CHEST errors in Table 1 in their article, "Tracheobronchopathy From Inhaled Corticosteroids" (Chest. 2017;152[6]:1296-1305). Full-Text PDF